BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/12/2023 9:13:35 AM | Browse: 119 | Download: 231
 |
Received |
|
2023-01-26 13:57 |
|
Peer-Review Started |
|
2023-01-26 13:59 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-03-08 17:20 |
|
Revised |
|
2023-03-13 20:20 |
|
Second Decision |
|
2023-04-07 01:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-07 07:12 |
|
Articles in Press |
|
2023-04-07 07:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-04-11 19:02 |
|
Typeset the Manuscript |
|
2023-05-02 12:28 |
|
Publish the Manuscript Online |
|
2023-05-12 09:13 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fan-Jie Qu, Shuang Wu and Yan Kong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yan Kong, MD, Professor, Department of Oncology, Affiliated Dalian Third People's Hospital of Dalian Medical University, No. 40 QianShan Road, Dalian 116033, Liaoning Province, China. kongkongyan2022@163.com |
| Key Words |
Fruquintinib; Tegafur-gimeracil-oteracil potassium(S-1); Advanced colorectal cancer; Progression-free survival; Case report |
| Core Tip |
After the failure of second-line standard therapy, effective treatment options for metastatic colorectal cancer (mCRC) are limited. Here, we describe a patient with advanced colorectal cancer with multiple metastases in both lungs. Oxaliplatin combined with 5-FU or capecitabine was given at the first line, and bevacizumab combined with irinotecan was given at the second line after disease progression, but treatment was interrupted due to recurrent grade 2 nausea and grade 1 diarrhea. He received targeted therapy with Fruquintinib from August 26th 2020 and responded well for 12 mo. After slow progression of lung metastases, PFS was again achieved over 13.5 mo by continued retention of Fruquintinib in combination with S-1 chemotherapy. Overall treatment duration was more than 25.5 mo. This case report is based on preliminary evidence showing that the combination of Fruquintinib with S1 chemotherapy double oral therapy resulted in longer PFS in patients with advanced CRC. |
| Publish Date |
2023-05-12 09:13 |
| Citation |
Qu FJ, Wu S, Kong Y. Oral fruquintinib combined with Tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report. World J Gastrointest Oncol 2023; 15(5): 902-910 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i5/902.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i5.902 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
